Previous 10 | Next 10 |
Aravive ( NASDAQ: ARAV ) has announced the appointment of Dr. Robert B. Geller as Chief Medical Officer . Dr. Geller will play a critical role in progressing Aravive’s portfolio of programs in ovarian, renal and pancreatic cancers. For further details see...
HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chief Medical Officer. Dr. Ge...
Aravive (NASDAQ:ARAV) has appointed Rudy Howard to succeed Vinay Shah as Chief Financial Officer, effective immediately. Vinay Shah has stepped down for personal reasons but will remain with the company as an advisor to ensure a smooth transition. Prior to joining Aravive, Mr. Howar...
HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Rudy Howard as Chief Financial Officer, effective tod...
Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022 Development of biomarker offers the potential of a first in class targeted therapy in renal cancer Company has a registrational path for potential accelerated approval as well as full approval ...
The following slide deck was published by Aravive, Inc. in conjunction with this event. For further details see: Aravive (ARAV) Investor presentations - Slideshow
HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D, DABT, Chief Executive Officer will present at the H.C. Wainwright Annual Glob...
Aravive press release (NASDAQ:ARAV): Q1 GAAP EPS of -$0.62. Revenue of $1.09M (+336.0% Y/Y). As of March 31, 2022, cash and cash equivalents were $65.8 million, compared to $59.4 million as of December 31, 2021. For further details see: Aravive GAAP EPS of -$0.62, revenue of $1.09M
Reported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCC Presented updated modeling data from batiraxcept clinical trials at the AACR annual meeting Dosed first patient in Phase 2 study of batiraxcept in clear cell Renal Cell Carc...
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it will host a Key Opinion Leader (KOL) Symposium on the GAS6-AXL signaling pathway and the Compa...
News, Short Squeeze, Breakout and More Instantly...
Amerityre Corp (AMTY) is expected to report for Q3 2024 CURO Group Holdings Corp. (CUROQ) is expected to report for Q1 2024 China Health Industries Holdings Inc (CHHE) is expected to report for Q3 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Anterix In...
Blue Ridge Real Estate Co. (BRRE) is expected to report for Q2 2024 Aravive Inc. (ARAV) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Golden Matrix Group Inc. (GMGI) is expected to report for Q2 2024 Bluejay Diagnostics Inc. (BJDX) is exp...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...